Cite

    Nishimura, R. et al. (n.d.). Effects of luseogliflozin, a sodium–glucose co‐transporter 2 inhibitor, on 24‐h glucose variability assessed by continuous glucose monitoring in Japanese patients with type 2 diabetes mellitus: a randomized, double‐blind, placebo‐controlled, crossover study. Diabetes, obesity & metabolism. 17 (8), pp. 800-804. [Online].